Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HK1 | P19367 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26987300 | 0.83 | POLB (0.43) | MAPTALDH1A1HPGDCISD2CA1 | |
| SCHEMBL28792118 | 0.81 | CA12 (0.47) | ALDH1A1HPGDCA1CA2CA9 | |
| SCHEMBL29683902 | 0.81 | CA12 (0.47) | ALDH1A1HPGDCA1CA2CA9 | |
| SCHEMBL3799307 | 0.81 | ALDH1A1 (0.54) | MAPTRXFP1ALDH1A1HPGDCISD2 | |
| SCHEMBL1601224 | 0.79 | RXFP1 (0.58) | MAPTRXFP1ALDH1A1HPGDCA1 | |
| SCHEMBL767484 | 0.78 | MAPT (0.58) | MAPTRXFP1ALDH1A1HPGDCISD2 | |
| SCHEMBL11137262 | 0.78 | CA12 (0.44) | MAPTALDH1A1HPGDCA1CA2 | |
| SCHEMBL2322798 | 0.78 | RXFP1 (0.56) | MAPTRXFP1ALDH1A1HPGDCA1 | |
| SCHEMBL1335275 | 0.76 | CA12 (0.57) | MAPTALDH1A1HPGDCA1CA2 | |
| SCHEMBL768559 | 0.75 | MAPT (0.51) | MAPTRXFP1ALDH1A1HPGDCISD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660003-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-11713311-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-01 | — | — | US | disclosed |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-08 | — | — | US | disclosed |
| US-11230541-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-3660003-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054874-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | MAPT 4634/4885RXFP1 2647/4885ALDH1A1 1322/4885 |
| US-11230541-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | MAPT 213/4885RXFP1 4102/4885ALDH1A1 3354/4885 |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | MAPT 213/4885RXFP1 4102/4885ALDH1A1 3354/4885 |
| US-11713311-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | MAPT 213/4885RXFP1 4102/4885ALDH1A1 3354/4885 |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | MAPT 213/4885RXFP1 4102/4885ALDH1A1 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.